Blue Mountain Hospital Dialysis is a medicare approved dialysis facility center in Blanding, Utah and it has 8 dialysis stations. It is located in San Juan county at 802 S 200 W, Blanding, UT, 84511. You can reach out to the office of Blue Mountain Hospital Dialysis at (435) 678-4624. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Blue Mountain Hospital Dialysis has the following ownership type - Non-Profit. It was first certified by medicare in July, 2009. The medicare id for this facility is 460056 and it accepts patients under medicare ESRD program.
| Name | Blue Mountain Hospital Dialysis |
|---|---|
| Location | 802 S 200 W, Blanding, Utah |
| No. of Dialysis Stations | 8 |
| Medicare ID | 460056 |
| Managed By | Independent |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 802 S 200 W, Blanding, Utah, 84511 | |
| (435) 678-4624 | |
News Archive
AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.
As the 5G mobile network launches in some UK cities, experts discuss whether there is any reliable evidence to suggest people should be worried.
Obesity increases a chronic kidney disease patient's risk of developing kidney failure. Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
› Verified 8 days ago
| NPI Number | 1114152527 |
| Organization Name | Dialysis Unit |
| Doing Business As | Blue Mountain Hospital |
| Address | 802 S 200 W Blanding, Utah, 84511 |
| Phone Number | (435) 678-3993 |
News Archive
AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.
As the 5G mobile network launches in some UK cities, experts discuss whether there is any reliable evidence to suggest people should be worried.
Obesity increases a chronic kidney disease patient's risk of developing kidney failure. Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
› Verified 8 days ago
| Dialysis patients with Hemoglobin data | 32 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 19 |
| Medicare patients who had average hemoglobin (hgb) greater than 12 g/dL | 3 |
News Archive
AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.
As the 5G mobile network launches in some UK cities, experts discuss whether there is any reliable evidence to suggest people should be worried.
Obesity increases a chronic kidney disease patient's risk of developing kidney failure. Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
› Verified 8 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 39 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 332 |
| Percentage of adult patients getting regular hemodialysis at the center | 99 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.
As the 5G mobile network launches in some UK cities, experts discuss whether there is any reliable evidence to suggest people should be worried.
Obesity increases a chronic kidney disease patient's risk of developing kidney failure. Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
› Verified 8 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Blue Mountain Hospital Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 39 |
| Hypercalcemia patient months | 333 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 40 |
| Patients with Serumphosphor less than 3.5 mg/dL | 12 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 16 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 25 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 28 |
| Patients with Serumphosphor greater than 7 mg/dL | 19 |
News Archive
AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.
As the 5G mobile network launches in some UK cities, experts discuss whether there is any reliable evidence to suggest people should be worried.
Obesity increases a chronic kidney disease patient's risk of developing kidney failure. Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
› Verified 8 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 42 |
| Patient months included in arterial venous fistula and catheter summaries | 354 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 69 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
News Archive
AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.
As the 5G mobile network launches in some UK cities, experts discuss whether there is any reliable evidence to suggest people should be worried.
Obesity increases a chronic kidney disease patient's risk of developing kidney failure. Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
› Verified 8 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 32 |
| Hospitalization Rate in facility | 118.8 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 251.7 |
| Hospitalization Rate: Lower Confidence Limit | 59.1 |
News Archive
AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.
As the 5G mobile network launches in some UK cities, experts discuss whether there is any reliable evidence to suggest people should be worried.
Obesity increases a chronic kidney disease patient's risk of developing kidney failure. Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
› Verified 8 days ago
The rate of readmission show you whether patients who were being treated regularly at Blue Mountain Hospital Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 19 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 34.8 |
| Readmission Rate: Lower Confidence Limit | 8.2 |
News Archive
AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.
As the 5G mobile network launches in some UK cities, experts discuss whether there is any reliable evidence to suggest people should be worried.
Obesity increases a chronic kidney disease patient's risk of developing kidney failure. Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
› Verified 8 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Blue Mountain Hospital Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.72 (As Expected) |
| SIR: Upper Confidence Limit | 4.68 |
| SIR: Lower Confidence Limit | .44 |
News Archive
AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.
As the 5G mobile network launches in some UK cities, experts discuss whether there is any reliable evidence to suggest people should be worried.
Obesity increases a chronic kidney disease patient's risk of developing kidney failure. Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
› Verified 8 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Blue Mountain Hospital Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 31 |
| Transfusion Rate in facility | 71.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 154.5 |
| Transfusion Rate: Lower Confidence Limit | 36.4 |
News Archive
AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.
As the 5G mobile network launches in some UK cities, experts discuss whether there is any reliable evidence to suggest people should be worried.
Obesity increases a chronic kidney disease patient's risk of developing kidney failure. Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
› Verified 8 days ago
The rate of mortality show you whether patients who were being treated regularly at Blue Mountain Hospital Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 140 |
| Mortality Rate in facility | 10.4 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 17.5 |
| Mortality Rate: Lower Confidence Limit | 5.7 |
News Archive
AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.
As the 5G mobile network launches in some UK cities, experts discuss whether there is any reliable evidence to suggest people should be worried.
Obesity increases a chronic kidney disease patient's risk of developing kidney failure. Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
› Verified 8 days ago
News Archive
AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.
As the 5G mobile network launches in some UK cities, experts discuss whether there is any reliable evidence to suggest people should be worried.
Obesity increases a chronic kidney disease patient's risk of developing kidney failure. Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
› Verified 8 days ago